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Introduction
Despite widespread implementation of cytologi-
cal screening in many countries, cervical cancer
represents a major cause of morbidity and mor-
tality. Worldwide, cervical cancer is the second
most common female cancer, claiming around
270,000 lives annually.1 Persistent infection with
human papillomavirus (HPV) is the most im-
portant etiological factor in cervical cancer and
its precursor lesions, cervical intraepithelial neo-
plasia (CIN), with HPV DNA being identified in
more than 99% of cervical cancers.2 In addition,
HPV has been associated with several other
human cancers including vulvar cancer, vaginal
and anal cancer, and a subset of head and neck
cancers.3 Although over 100 genotypes of HPV
have been identified, only several are considered
“high risk” due to their oncogenic potential, no-
tably HPV-16 and HPV-18.4
HPVs are non-enveloped viruses containing a
circular double-stranded DNA genome of around
8000 base pairs, which preferentially infect squa-
mous epithelial cells. The genome encodes at least
six early genes (E1, E2, E4, E5, E6, and E7) and two
late genes (L1 and L2). The early genes regulate
viral DNA replication while the late genes encode
the viral capsid for packaging newly synthesized
virions (Figure 1). HPV infects the basal cells 
of the cervical epithelium through microtrauma;
however, the majority of HPV infections are self-
limiting and transient.5 In persistent infection,
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Human Papillomavirus (HPV) has been associated with several human cancers, including cervical cancer,
vulvar cancer, vaginal and anal cancer, and a subset of head and neck cancers. Thus effective vaccination
against HPV provides an opportunity to reduce the morbidity and mortality associated with HPV. The
Food and Drug Administration of the United States has approved two preventive vaccines to limit the
spread of HPV. However, these are unlikely to impact upon HPV prevalence and cervical cancer rates for
many years. Furthermore, preventive vaccines do not exert therapeutic effects on pre-existing HPV infec-
tions and HPV-associated lesions. In order to further impact upon the burden of HPV infections world-
wide, therapeutic vaccines are being developed. These vaccines aim to generate a cell-mediated immune
response to infected cells. This review discusses current preventive and therapeutic HPV vaccines and their
future directions. [J Formos Med Assoc 2010;109(1):4–24]
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the expression of the HPV genome is correlated
to the maturation of the infected cell.
Immature epithelial cells in the basal layer
allow expression of the HPV early genes whereas
in terminally differentiated cells, transcription
shifts to the late genes, allowing the newly as-
sembled virions to be released away from the
submucosa, the site of immune surveillance. The
HPV genome is usually found in episomal form
in productive infection. However, high risk HPVs
may integrate into the host genome in some per-
sistent infections. This integration causes dele-
tion of some of the early genes (E2, E4, and E5)
as well as the late genes L1 and L2. E2 is a master
regulator of the viral genome and notably a tran-
scriptional repressor of the E6 and E7 genes. Loss
of E2 through integration allows upregulation of
E6 and E7 transcription. E6 and E7 are oncogenes,
capable of inactivating tumor suppressor p53 and
retinoblastoma, leading to genomic instability
and repression of apoptosis.6 HPV utilizes several
mechanisms to avoid and modulate the immune
system, allowing HPV to freely proliferate within
cells. An understanding of these defense mecha-
nisms, HPV virology and its role in tumorigene-
sis has facilitated the development of preventive
and therapeutic vaccines to stimulate the immune
system into responding to HPV. While preventive
vaccines aim to block initial HPV entry into 
epithelial cells, therapeutic vaccines generate a 
T-cell immune response to eliminate existing
HPV infection and HPV-associated neoplasms.
Preventive Vaccines
Current strategy in preventive vaccines utilizes
the capsid proteins L1 and L2 as target antigens,
inducing antibodies to neutralize and prevent
entry of HPV into cells. Expression of recombinant
Figure 1. HPV-16 genome and protein function. HPV-16 has a 7904 base pair, double-stranded circular DNA genome.
The transcriptional promoter is designated P97. AE and AL are the early and late polyadenylation sites, respectively. The
viral long control region (LCR) contains transcriptional and replication regulatory elements. The HPV-16 genome contains
six early genes (E1, E2, E4, E5, E6, E7) and two late genes (L1, L2). The late genes comprise the viral capsid while the
early genes are involved in viral replication. E1 regulates episomal viral DNA replication. E2 is a transcriptional regulator
of E6 and E7. E4 is involved in cytoskeletal reorganization. E5 is involved in cellular transformation. E6 and E7 are respon-
sible for the induction of malignant transformation by binding to p53 and retinoblastoma (Rb) protein, respectively.
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L1, the major component of the capsid, in vari-
ous cell types results in spontaneous assembly of
virus-like particles (VLPs), which are immuno-
logically and morphologically similar to HPV
virions.7–9 Vaccination of animal models with L1
VLPs protects them against subsequent exposure
to the homologous virus. The main focus of pre-
ventive vaccines has been on HPV-16 and HPV-
18 which together account for around 70% of
cervical cancers.10 Clinical trials of L1 VLP vac-
cines in seronegative healthy volunteers have
proven their immunogenicity and safety, produc-
ing high titers of neutralizing IgG antibodies, up
to 40 times those found in natural infection with
HPV-16.11
Two preventive vaccines have recently been 
licensed for use: Gardasil and Cervarix (Table 1).
Gardasil is a quadrivalent vaccine containing re-
combinant L1 VLPs for HPV genotypes 6, 11, 16,
and 18 whereas the bivalent vaccine Cervarix con-
tains L1 VLPs for HPV-16 and HPV-18. The Food
and Drug Administration of the United States
advisory panel has recently voted that Gardasil
be approved for use in males to reduce HPV-
associated cancers in males, prevent genital warts
and reduce transmission to uninfected women.12
The seroconversation rates for Cervarix and
Gardasil is 97.5% or higher in women.13–16 The
antibody response generated is unfortunately
type-restricted to those HPV genotypes contained
within the vaccine. However, there is some low-
level cross-protection against other closely related
genotypes.17 Despite this partial cross-protection,
a preventive vaccine would need to contain the
eight most common HPV types found in cancer to
create > 90% protection against cervical cancer—
a costly and complex processes.18 Ongoing stud-
ies show continued protection for up to 6.4 years
post vaccination with HPV-16 and HPV-18 L1
VLPs, as well as some cross-protection to HPV-45
and HPV-31.18 One monovalent HPV-16 L1 vac-
cine with an aluminium hydroxyphosphate sulfate
adjuvant shows 86% of volunteers are seroposi-
tive at an average 8.5 years, where mean HPV-16
antibody titers were 71.7 mMU/mL in contrast 
to 150 mMU/mL giving 4 years.20,21 A recent trial
Table 1. Comparison of Cervarix and Gardasil preventive HPV vaccines
Cervarix Gardasil
Manufacturer Merck & Co GlaxoSmithKline
HPV types 16, 18 6, 11, 16, & 18
Antigen (/dose) 20 μg HPV-16 L1 20 μg HPV-6 L1
20 μg HPV-18 L1 20 μg HPV-11 L1
40 μg HPV-16 L1
20 μg HPV-18 L1
Antigen source Baculovirus Yeast
Adjuvant AS04 composed of: 225 μg aluminum 
500 μg aluminium hydroxide hydroxyphosphate sulfate
50 μg 3-O-desacyl-4-monophosphoryl 
lipid A
Recommended administration IM (0.5 mL dose at 0, 1, 6 mo) IM (0.5 mL dose at 0, 2, 6 mo)
Approx price(/dose) US$100 US$120
Approved for ages 10–25 9–26
Antibody titers (1 month after HPV-16: 107 times HPV-6, 11 times;
completed vaccination course HPV-18: 82 times160 HPV-11, 7 times;
compared to natural infection) HPV-16, 105 times;
HPV-18, 19 times161
Geometric mean antibody titers HPV-16: 31715 HPV-16: 8682
at 7 months (aged 18–26) HPV-18: 13732 HPV-18: 1886
demonstrated the safety, immunogenicity, and
efficacy of quadrivalent HPV-6, 11, 16, and 18)
recombinant vaccine in women aged 24–45
years. The quadrivalent HPV vaccine was found
to be efficacious in this age group of women not
infected with the relevant HPV types at enrol-
ment.22 The quadrivalent vaccine was also tested
against high-grade cervical and external genital
lesions including vulvar and vaginal lesions and
its efficacy was found to remain high through 
42 months post vaccination.23 Another recent
trial tested the efficacy of a prophylactic ASO4
adjuvanted bivalent L1 virus-like-particle vaccine
against infection with HPV-16 and HPV-18 
in young women aged 15–25 years. The vaccine
was found to demonstrate prophylactic efficacy
against CIN2+ associated with HPV-16 or HPV-
18.24 It is estimated that a reduction in cervical
cancer rates will not be witnessed until at least
20 years of mass vaccination due to the high
prevalence in the population and slow process of
carcinogenesis.
Unfortunately, L1 VLP vaccines are expensive
and require repeat vaccination and specific con-
ditions for storage. For example, the vaccines
must be refrigerated and delivered via intramus-
cular injection, introducing several hurdles to
mass vaccination in developing countries, which
carry the highest burden of HPV-related disease.25
Second generation vaccines are attempting to
broaden HPV type coverage, be thermo-stable,
inexpensive and have needle-free administration
methods while maintaining long-term protec-
tion with a single dose.
Future prospects of preventive vaccines
Development of future generations of preventive
vaccines must address two main issues: (1) lower-
ing the cost in order to increase availability of the
vaccine to developing countries; and (2) to in-
crease the number of HPV types covered in order
to maximize protection against HPV-associated
malignancies. An attractive approach to substan-
tially reduce the cost of producing L1 vaccines is
the employment of L1 capsomers. The current L1
vaccines, Cervarix and Gardasil, are produced in
insect cells and yeast respectively. Production of
the vaccine in Escherichia coli may be a cheaper
option. Use of recombinant E. coli to produce
these L1 capsomers has demonstrated success in
inducing protective antibodies in animal mod-
els.26–28 Additionally, L1 capsomer vaccines are
stable at room temperature, negating the need
for refrigeration. Trials with VLP vaccines have
investigated needle-free administration routes
such as transdermal application29 and nasal in-
halation,30 which could be of practical use in fu-
ture capsomer vaccines.
To overcome the genotype restriction of L1
vaccines, the highly conserved and thus cross-
reactive L2 can be employed. L2-based vaccines
can also be produced using E. coli to reduce costs
and increase availability to the developing world.
However, L2 vaccines are less immunogenic than
their L1 counterparts, creating comparatively lower
titers of neutralizing antibodies. This may be
overcome through the use of strong adjuvants,
such as Toll-like receptor 2 agonists, providing 
a promising future vaccine.31 Another method of
creating broader protection is through poly-
valent L1 vaccines containing VLPs for several
HPV types, for example Merck is currently re-
cruiting for Phase II clinical trials of a nine-valent
vaccine, V503.32
Several factors highlight the need for a thera-
peutic, rather than preventive, vaccine. The most
pressing of these factors is the high prevalence of
existing HPV infection worldwide, on which pre-
ventive vaccines make little impact. Since over
80% of cervical cancer cases occur in the devel-
oping world, preventive vaccines would need to
be in widespread use for many years to reduce
this figure, which is currently improbable in the
near future due to logistics and cost. Further-
more, in HPV-associated malignancies where ge-
nomic integration has occurred, infected cells
may no longer express L1 or L2. To exert a thera-
peutic effect, a different vaccine target antigen is
needed which is expressed constitutively in HPV-
associated tumor cells. Such a vaccine may exert
an immediate effect on the mortality and mor-
bidity of HPV-associated lesions.
Perspectives for HPV vaccines
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Therapeutic Vaccines
The HPV E6 and E7 antigens represent ideal tar-
gets for therapeutic vaccines since these are con-
stitutively expressed in HPV-infected cells and not
healthy cells. E6 and E7 are essential to the in-
duction and maintenance of cellular transfor-
mation, and thus are unlikely to be lost in an
attempt to evade the immune system.6,32
A number of therapeutic vaccines have been
developed targeting E6 and E7 including live vec-
tor vaccines, peptide/protein-based vaccines, cell-
based vaccines and nucleic acid-based vaccines,
each with advantages and disadvantages (Table 2).
These vaccines likely control HPV infection
through cell-mediated immunity (Figure 2) and
many have shown promise in both preclinical
and clinical trials.
Live vector-based vaccines
Live vector-based vaccines encompass both bac-
terial and viral vectors, many of which are avail-
able depending on the desired effect. These vectors
are highly immunogenic as they replicate within
host cells and facilitate spread of antigen. Vector-
based vaccines can deliver the antigens E6 and
E7 to the dendritic cells (DCs), stimulating anti-
gen expression through MHC class I (to CD8+
cytotoxic T cells) and MHC class II (to CD4+
helper T cells). However, live vectors inherently
pose a potential safety risk, especially to immuno-
compromised individuals. Another disadvantage
is the generation of neutralizing antibodies, lim-
iting the efficacy of repeat immunization, as well
as the possibility of pre-existing immunity to the
vector being employed.
Bacterial vectors
Attenuated bacteria can deliver genes or proteins of
interest, such as E6 and E7, to antigen-presenting
cells. Various bacterial vectors have been explored
in HPV therapeutic vaccines including Listeria
monocytogenes,34,35 Lactobacillus lactis,36,37 and
Lactobacillus plantarum.38 Listeria is a promising
vector due to its ability to infect monocytes and
macrophages and secrete listeriolysin O, allowing
evasion from phagosomes. Literiolysin O allows
Listeria to be present in both the cell cytoplasm
and endosomal compartments, resulting in anti-
gen presentation through both MHC class I and
II pathways, inducing CD4+ and CD8+ immune
responses.39 In preclinical trials, Listeria-based E7
vaccines were shown to cause regression of im-
planted solid tumors in HPV-16 E6/E7 transgenic
mice.35 Currently, a clinical trial is ongoing with
a Listeria-based vaccine for HPV-16 E7 (Lovaxin
C) in women with advanced cervical cancer.40
Listeria-based vaccine potency can be further en-
hanced by the means of encoding recombinant
proteins composed of HPV E6/E7 antigen fused
to immunostimulatory molecules, for example,
through fusion of lysteriolysin O with E7.41 Re-
cently, Maciag et al utilized this method and re-
ported the first clinical use of a live-attenuated
Listeria monocytogenes vaccine that secretes HPV-
16 E7 antigen fused to a fragment of listeriolysin
O (Lm-LLO-E7).42 In this Phase I safety clinical
trial, Lm-LLO-E7 infusion was found to be safe
and well-tolerated in end stage cervical cancer
patients who had failed prior chemotherapy, 
radiotherapy and/or surgery. Hence, there is po-
tential for bacterial vectors to not only serve as
vaccine vectors but possibly as cancer immuno-
therapeutics as well.
Viral vectors
Highly efficient infection rates and expression of
encoded antigen make viral vectors a feasible op-
tion in therapeutic HPV vaccines. Viruses that have
been used include adenovirus,43 adeno-associated
virus,44 vaccinia virus,45 and alphaviruses, such as
the Venezuelan equine encephalitis virus.46,47
Vaccinia’s large genome and highly infectious
nature make it a promising vector. Vaccinia-based
vaccines include vaccinia encoding fusion of E7
and calreticulin (CRT) to enhance MHC I pro-
cessing in DCs,45,48 and vaccinia encoding E7 and
listeriolysin O,48 to facilitate MHC I and II pres-
entation. Phase I/II clinical trials have shown that
a recombinant vaccinia virus expressing the HPV-
16 and HPV-18 E6 and E7 fusion protein, TA-
HPV, induces potent antigen-directed antibody
Perspectives for HPV vaccines
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and cytotoxic responses in patients with CIN III
and cervical cancer.49–51
Adenoviruses have also shown promising 
results. A recent study demonstrated that vacci-
nation with replication-deficient adenoviruses
encoding CRT/E7 fusion protein conferred im-
munity to an E7-expressing tumor challenge, and
eradicated established tumors in mice.43 Creation
of an adenovirus vaccine encoding a fusion pro-
tein of hepatitis B surface antigen and HPV-16 E7
has been described. Vaccination with adenovirus
vector encoding hepatitis B surface antigen/E7
fusion protein stimulated E7-specific antibody
and CD8+ T cell immune responses in vaccinated
mice.52 The adeno-associated viruses can also be
engineered to express E7 linked to Mycobacterium
tuberculosis heat shock protein 70 (hsp70) enhanc-
ing MHC class I antigen processing in a number
of ways, such as through translocation of E7 to
sub-cellular compartments, inducing CD8+ T cell
immune responses.53,54
RNA viruses, such as the Semliki Forest virus
can also be utilized as live vectors. SFV expressing
HPV-16 E7 can induce E7-specific cytotoxic T cells
in HPV-transgenic mice.55 This response can be en-
hanced through the co-administration of inter-
leukin (IL)-12, inhibiting tumor angiogenesis.56,57
The future of therapeutic live vector-based
vaccines requires identification of efficient bac-
terial and viral vectors and enhancement of the
immunogenicity of these vector-based vaccines
through expression of cytokines or co-stimulatory
molecules. A further hurdle to overcome is the
generation of neutralizing antibodies upon first
exposure to the vaccine; a means to prevent this
is required to allow effective repeated admin-
istration. A recent study showed that COX-2 
inhibitors, such as Celecoxib, can prevent the
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Figure 2. Therapeutic HPV vaccines. A number of therapeutic vaccines have been developed targeting HPV E6 and/or
E7 antigen(s), including live vector-based vaccines, peptide/protein-based vaccines, nucleic acid-based vaccines and
cell-based vaccines. These vaccines likely control HPV infection through cell-mediated immunity. Dendritic cells (DCs)
prime naïve T cells through MHC: Antigen (Ag) complex with the help of costimulatory molecules (B7 on the DC and
CD28 on the T cell). Antigens are processed and presented to CD4+ T cells via MHC class II pathway and presented to
CD8+ T cells via MHC class I pathway. The primed effector T cells are subsequently HPV-antigen-specific T cells.
Activated CD8+ T cells kill tumor cells by inducing apoptosis in the target cells. Induction of CD4+ T cell help can aug-
ment the CD8+ T cell immune response, supplementing tumor killing.
generation of neutralizing antibodies to vaccinia,
allowing repeated administration without losing
infectivity, a promising advance.58
Peptide/protein-based vaccines
Administered peptides and proteins derived from
HPV antigens are taken up by DCs, processed and
expressed via MHC II and/or I to the appropriate
CD4+/CD8+ T cell.
Peptide-based vaccines
Peptide vaccines are safe, stable and easy to 
produce. However, widespread use is restricted
by the necessity to identify immunogenic epi-
topes corresponding to the polymorphic MHC
molecules within the population. This can be
partially overcome through the use of overlap-
ping long peptides that contain several epitopes
of E6/E7. Preclinical studies in mice and rabbits
have shown that long E6/E7 peptides are able 
to induce antigen-specific T cells in all animal
subjects.59,60
Due to the poor immunogenicity of peptide
vaccines, adjuvants such as chemokines, cyto-
kines and Toll-like receptor ligands, must be si-
multaneously administered. Examples of these
include Granulocyte/macrophage colony stimu-
lating factor (GM-CSF) to activate DCs (58), the
co-stimulatory 4-IBB ligand (59), mutant cholera
toxin62 and CpG oligodeoxynucleotides, which
mimic bacterial danger signals.63,64
Despite these limitations, several peptide vac-
cines have advanced to clinical trials. Phase I tri-
als in end-stage cervical cancer patients employing
HPV-16 E6 and/or E7 long peptides with the ad-
juvant Montanide ISA-51 show a significant E6-
specific T cell response.65 A similar study using
HPV-16 E6 and E7 long peptides with Mon-
tanide ISA-51 in women with HPV-16+ cervical
cancer induced E6-specific CD4+ and CD8+ im-
mune responses in all six patients, and E7-specific
CD4+ and CD8+ immune responses in 5 out of 6
patients, an encouraging result.66
The future of peptide-based vaccine relies on
augmentation of their immunogenicity and epi-
tope enhancement to prevent degradation and
thus prolong antigen presentation. Furthermore,
targeting delivery specifically to DCs will addi-
tionally increase antigen presentation, for exam-
ple, using liposomal vehicles, which also act as 
a potent adjuvant. A recent study utilizing this
method created an E7 lipopeptide vaccine, which
greatly enhanced the E7-specific CD8+ activity in
TC-1 tumor-bearing mice compared to E7 pep-
tide alone.67
Protein-based vaccines
Protein-based vaccines contain all antigenic epi-
topes, circumventing the MHC-restriction limita-
tion associated with peptide vaccines. However,
while protein-based vaccines are safe, they suffer
low immunogenicity. Strategies to improve their
potency are similar to those employed in peptide-
based vaccines. Unfortunately, due to their exoge-
nous nature, protein-based vaccines are presented
via MHC class II pathway and thus predom-
inantly generate an antibody response, rather
than a T cell response, necessitating strategies 
to create a predisposition for the MHC I presen-
tation pathway.
Adjuvants trialled include liposome-polyca-
tionic-DNA carrier particles68 and the saponin-
based ISCOMATRIX,69 both which enhance
endogenous processing and thus MHC I expres-
sion of antigen. Creation of fusion proteins to
target the antigen to DCs can increase MHC I
presentation and thus CD8+ responses. Exam-
ples of these include HPV-16 E7 linked to
Bordetella pertussis adenylyl cyclase, which inter-
acts with the DC’s integrin receptors,70 and fu-
sion of the translocation domain of Pseudomonas
aeruginosa exotoxin A with HPV-16 E7 to target
E7 to the MHC class I presentation pathway.71
A similar strategy includes fusion of antigen to
heat shock proteins that act as molecular chaper-
ones to target antigen to DCs for cross-priming,
stimulate DC maturation and induce cytokines.72
Such examples include a fusion of Mycobacterium
hsp65 with HPV-16 E7 (HspE7)73 and a fusion
of hsp70, CRT, and HPV-16 E7.74
A clinical trial of HspE7 in 58 women with
CIN III generated a complete pathologic response
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(defined as a LEEP specimen being negative for
CIN) in 13 and a partial clinical response (de-
fined as a colposcopic lesion regression of > 50%
based on measurements made on a grid form) in
32 women. However, it is difficult to determine
if this observed regression was contributed by
spontaneous regression.75
Another protein-based vaccine that has pro-
gressed to clinical trials is TA-CIN, containing a
fusion protein composed of HPV-16 L2, E6, and
E7. Injection of the vaccine into 40 healthy vol-
unteers induced antibody response to L2 in all,
and T cell-mediated responses to HPV-16 E6 and
E7 in eight of the 11 patients receiving the highest
dose.76 The inclusion of L2 within this vaccine
offers a new step in the evolution of HPV vaccines
by combining both preventive and therapeutic
vaccines. In general, the future of protein-based
vaccines relies upon enhancement of immuno-
genicity and CD8+ T cell response through adju-
vant and fusion protein strategies.
Whole cell vaccines
Dendritic cell-based vaccines
Circumvention of HPV-induced immunosup-
pression can be achieved by delivering antigenic
peptides directly to DCs in those with HPV-
associated lesions. In such a setting, DCs act as
natural adjuvants.77 Unfortunately, the prepara-
tion involved is costly and time-consuming and
consequently widespread use is currently im-
practical. A lack of agreed standards and cul-
turing techniques for the generation of such
vaccines adds a further challenge. Various meth-
ods employed in preparing DCs ex vivo include
the usage of viral vectors,78,79 transfection with
DNA or RNA encoding antigen,80,81 and pulsa-
tion of DCs with antigenic protein, peptide or
tumor cell lysates.82–85
T-cell mediated apoptosis limits the lifespan
of DCs and their ability to prime T cells. There-
fore, methods to prolong DC survival enhance
antigen-specific responses. One way to achieve
this is through transfection of DCs with short in-
terfering RNA (siRNAs) intended to interfere with
the expression of pro-apoptotic molecules. DCs
loaded with E7 and transfected with siRNA tar-
geting the pro-apoptotic Bak and Bax proteins
generate enhanced E7-specific CD8+ activation
and antitumor effects in mice.83 Similarly, E7-
presenting DCs transfected with siRNA to Bim,
Bid, Bak, Bax and caspase 8 found that siRNA 
to Bim generated the strongest E7-specific CTL
response in mice.84
In clinical trials, autologous DCs loaded with
HPV-16 or HPV-18 E7 antigen were administered
to women with HPV-16+ or HPV-18+ late-stage
cervical cancer respectively. E7-specific T cell re-
sponses were present in four out of 11 patients.86
A similar study of DCs loaded with HPV-16 or
HPV-18 E7 co-administered with IL-2 in HPV-
16/18+ refractory cervical cancer patients showed
E7-specific CD4+ responses in two of four 
patients and E7-specific CD8+ responses in all
four patients.87 An ongoing clinical study using
DC-based vaccines with HPV-16 E7 is currently
underway in patients with HPV-16+ recurrent
cervical cancer at the National Taiwan University
Hospital.88
Antigen-loaded DCs must travel to lymphoid
organs in order to prime T cells and as a result,
the route of administration of DC-based vac-
cines is an important issue. Methods previously
used include intramuscular, subcutaneous, intra-
venous and intranodal delivery. Improvement
strategies for future generations of DC-based vac-
cines include elucidating the most effective de-
livery route and developing methods to enhance
antigen loading and prolong DC survival.
Tumor cell-based vaccines
Isolating and manipulating tumor cells ex vivo
to express immunomodulatory proteins can en-
hance their immunogenicity in vivo. The cyto-
kines IL-2,89 IL-12,90,91 and GM-CSF91,92 have been
trialled in mice with HPV-16 induced tumors.
Clinical studies have not yet begun for HPV-
associated tumor-based vaccines, although tumor-
based vaccines have undergone clinical trials in
melanoma, pancreatic cancer and renal cell carci-
noma.93 These vaccines are advantageous in that
tumour antigens do not have to be identified.
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However, we already hold this knowledge for cer-
vical cancers, limiting the usefulness of this ap-
proach for the development of cervical cancer
vaccines.
Some reluctance surrounds tumor-based vac-
cination due to the risk of seeding new cancers in
patients, preventing clinical trials in healthy in-
dividuals or those with mild CIN. Due to the na-
ture of these vaccines, their potency and purity
may be inconsistent and must be individualized,
creating additional problems for clinical studies.
Nucleic acid-based vaccines
DNA-based vaccines
Naked DNA is safe, stable, relatively easy to man-
ufacture on a large scale at high purity and capable
of sustaining antigen expression in cells longer
than RNA or protein vaccines. DNA vaccines can
be repeatedly administered, as they do not gen-
erate neutralizing antibodies. Although no sup-
portive evidence currently exists, there is a risk
that DNA vaccines could integrate into the host
genome. Furthermore, administering HPV E6 and
E7 DNA may cause cellular transformation as they
are oncogenes. However, this is addressed through
modification of E6 and E7 DNA into proteins 
incapable of oncogenic transformation.
An important limitation of DNA vaccines is
their intrinsic low immunogenicity due to an in-
ability to amplify or spread from transfected cells
into surrounding cells in vivo. To overcome this,
strategies to enhance DNA vaccine potency have
been developed, taking into consideration the
central role that DCs play in vaccine-mediated
immunity. Strategies include: (1) increasing num-
bers of DCs expressing antigen; (2) enhancing
antigen processing and presentation in DCs; and
(3) improving the interaction between DCs and
T cells.94,95
Increasing the antigen-expressing/
antigen-loaded DC population
Delivery methods targeting DNA directly to areas
rich in DCs increase the population of DCs pre-
senting the antigen. Intradermal administration
via gene gun ballistically delivers gold particles
coated in DNA directly to the immature DCs of
the skin, the Langerhan cells. This route of admin-
istration is convenient and a potent method of
DNA delivery. Head-to-head comparison shows
that the gene gun requires the lowest dose to
generate a comparable antigen-specific CD8+
T cell immune response, compared to the biojec-
tor or intramuscular injection.96 Unfortunately, the
DNA dose that can be delivered with each shot
of the gene gun is limited,97 which may necessi-
tate multiple administration sites, risking local
side effects. Another effective administration
method is the combination of intramuscular in-
jection with electroporation. Electroporation en-
hances DNA uptake through the application of a
small electric current, creating large numbers of
muscle cells expressing the desired antigen and
increasing release of antigen, which local DCs can
then process and present through the MHC class I
pathway. Electroporation can also induce cyto-
kine release, creating a favourable environment
for the DCs. A Phase I trial is currently underway
delivering VGX-3100, a DNA vaccine targeting
HPV-16 and HPV-18 E6 and E7, via intramuscu-
lar injection and electroporation in patients with
a diagnosis of CIN II/III.98 A recent study com-
paring several methods of DNA administration
found the highest numbers of E7-specific CD8+
were produced through intramuscular injection
with electroporation.99 Other novel methods to
enhance DNA delivery include laser100 and mi-
croencapsulation of DNA.101
Since DNA vaccines are unable to spread be-
tween cells, the linkage of HPV antigen with pro-
teins capable of intercellular transport in the
context of DNA vaccination allows this spread of
antigen in cells transfected with DNA. One ex-
ample is the use of DNA encoding both HPV-16
E7 and herpes simple virus 1 VP22, which has
been shown to have intercellular trafficking prop-
erties. Although questions have been raised as to
whether VP22 transports DNA between cells, or
if this is a fixation artifact, vaccinated mice un-
equivocally generate around a 50-fold increase
in the number of E7-specific CD8+ compared to
vaccination with wild-type E7 DNA.102 Further
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strategies to enhance DNA-encoded antigen up-
take by DCs include linkage of HPV antigen to
molecules that target the antigen to the DC sur-
face, such as FMS-like tyrosine kinase 3 ligands103
and heat shock proteins, which binds with scav-
enger receptors on DCs, such as CD91.96,104
Improving antigen expression, processing 
and presentation in DCs
Antigen expression can be increased through co-
don optimization, which replaces codons in-
frequently used by the host cells with more
commonly used codons to enhance translation
of the encoded antigens in cells transfected with
DNA. In preclinical mouse models, CD8+ T cell
immune responses and antitumor effects are en-
hanced through codon optimization of HPV
DNA vaccines.105–108
A second strategy to enhance antigen expres-
sion is the application of demethylation agents.
There is reduced expression of DNA when meth-
ylated, and thus demethylating agents upregu-
late gene expression. A DNA vaccine encoding
CRT plus E7 combined with the demethylation
agent 5-aza-2’-deoxycytidine upregulates CRT/E7
expression in mice, enhancing anti-tumor effects
against an E7-expressing tumor.109
Antigen-specific CD8+ T cell responses rely
upon presentation of antigen via MHC class I 
on DCs. To increase MHC class I processing,
HPV E7 DNA can be linked with molecules 
that localise antigen to the endoplasmic reticu-
lum110 or that facilitate proteasome degrada-
tion.111 Other MHC I targeting proteins trialled
in HPV DNA vaccines to enhance cross-priming
include M. tuberculosis hsp70,112 CRT,113–115 the
heat shock protein Gp96,116 the translocation
domain of Pseudomonas aeruginosa exotoxin A117
and γ-tubulin which targets HPV antigen to the
centrosomal compartment, rich in proteasomes.118
All of these show improvement in MHC I presen-
tation of the HPV E6/E7 antigen, inducing po-
tent CD8+ T cell immune responses to the DNA
vaccines.
MHC I single-chain trimer (SCT) technology
can be utilized to circumvent antigen processing
and presentation altogether. DNA vaccines encod-
ing antigenic peptide is linked to β2-microglobulin
and MHC class I heavy chain genes. The gene en-
coding the SCT is transcribed and expressed on
the DC surface as MHC I molecules already loaded
with the desired peptide. HPV-16 E6 SCT vac-
cines greatly increase E6-specific CD8+ T cell im-
mune response in vaccinated mice, protecting
them from a lethal challenge of E6-specific TC-1
tumor cells.119
MHC class II processing can also be enhanced,
resulting in greater CD4+ T cell responses to aug-
ment CD8+ T cell responses. DNA vaccine encod-
ing E7 antigen linked to the sorting signal peptide
of lysosomal-associated membrane protein 1 has
been shown to generate greater numbers of E7-
specific CD4+ and CD8+ cells and antitumor 
effects in vaccinated mice than wild type E7.120
A second way to target antigen through the MHC
class II processing pathway is through the use 
of the invariant chain (Ii). Substitution of the
CLIP region of Ii, which normally occupies the
antigen peptide-binding groove of MHC II to
prevent premature binding of MHC class II mol-
ecules to antigenic peptides, with a T helper epi-
tope such as the pan-DR helper T lymphocyte
epitope (PADRE), allows presentation of PADRE
via MHC II.121 A DNA vaccine encoding this 
(Ii-PADRE) generates significant PADRE-specific
CD4+ responses in vaccinated mice and co-
administration of Ii-PADRE DNA with HPV E7
DNA elicits potent E7-specific CD8+ responses
compared to E7 DNA co-administered with un-
modified Ii.121 Recent advances show that both
MHC I and II expression are regulated by CIITA,
and thus administering DNA for CIITA with
CRT/E6 DNA leads to enhanced E6-specific
CD8+ T cell immune responses in vaccinated
mice, which can be further improved with co-
administration of Ii-PADRE DNA.122
Enhancing DC and T cell interaction
Strategies to enhance DC and T cell interaction
may rely upon prolonging DC survival, increasing
DC expression of cytokines and blocking nega-
tive regulation of DC activation.
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Once DCs have primed naive T cells, they be-
come the targets of these effectors cells and un-
dergo apoptosis. Inhibiting this T cell-mediated
apoptosis allows DCs to prime a greater number
of T cells and can be achieved through the use of
anti-apoptotic proteins (Figure 3A). For example,
DNA encoding E7 co-administered with DNA
for inhibitors of apoptosis, such as Bcl-xL, Bcl-2,
X-linked inhibitor of apoptosis protein and
dominant-negative capsases has been shown to
enhance E7-specific CD8+ responses in mice.123
However, introduction of DNA encoding anti-
apoptotic proteins raises concerns of oncogenic-
ity. This may be alleviated through the use of
siRNA to instead transiently silence the expres-
sion of pro-apoptotic proteins. SiRNA targeting
DCs prime naïve T cells
CD8+
T cell
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Figure 3. Strategies to improve DC-T cell interaction in enhancing therapeutic DNA vaccine potency. (A) Prolonging DC
survival. Once DCs have primed naïve T cells, they can become the target of these effector T cells. The use of short inter-
fering RNA targeting key pro-apoptotic proteins such as Bak and Bax can transiently silence expression of Bak and Bax,
improving DNA-transfected DC resistance to apoptosis and improving DC-T cell interaction. (B) Prevention of activated
CD8+ T cell apoptosis. The Fas ligand (FasL) found on the surface of DCs is a pro-apoptotic signalling protein that binds
to the Fas receptor on T cells, causing them to undergo apoptosis. Creation of DNA encoding small hairpin RNA (shRNA)
to block FasL can prevent apoptosis of activated T cells and improve DC-T cell interaction.
the key proapoptotic proteins Bak and Bax with
the E7 DNA vaccine improves DNA-transfected
DC resistance to apoptosis and enhances CD8+
antitumor effects in mice.124 A recent study es-
tablished that DNA encoding connective tissue
growth factor linked to E7 can prolong survival
of DCs, generating potent E7-specific antitumor
responses without any oncogenic risk.125
Preventing activated T cell apoptosis is another
way to enhance overall CD8+ responses (Figure
3B). The Fas ligand found on the surface of DCs
is a pro-apoptotic signalling protein that binds
to the Fas receptor on T cells causing them to 
undergo apoptosis. Creation of DNA encoding
small hairpin RNA to block Fas ligand allows co-
administered E7 DNA to generate significant E7-
specific CD8+ responses and antitumor effects in
vaccinated mice.126
Enhancing stimulatory cytokine release from
DCs further improves DC and T cell interaction.
DNA-encoded cytokines can be included within
the E6/E7 DNA vaccine, for example GM-CSF,127
IL-2,128 and IL-12.129 Combining HPV E7 DNA
vaccines with DNA encoding sequence-optimized
(as opposed to wild type) IL-2 and IL-12 as adju-
vants caused tumor regression in mice through
E7-specific CD8+ responses.108
Several DNA vaccines have translated to clini-
cal trials. A microencapsulated DNA vaccine 
encoding several HLA-A2-restricted HPV-16 E7
epitopes (ZYC-101) has been tested in patients
with HPV-16+ CIN II/III, causing complete histo-
logical response in five of the 15 women and 
E7-specific T cell responses in 11 of the 15 pa-
tients.130 An updated version of this, ZYC-101a,
contains HPV-16 and HPV-18 E6 and E7-derived
epitopes and was studied in a Phase II trial in pa-
tients with CIN II/III lesions providing resolu-
tion in 70% of those patients aged < 25, although
this may be attributable to spontaneous resolu-
tion.131 One DNA vaccine encoding HPV-16 E7,
modified through the abolition of the Rb-binding
site, was linked to M. tuberculosis hsp70 and ad-
ministered to women with CIN II/III. Results 
revealed that those receiving the maximum dose
had detectable E7-specific CD8+ T cell responses
and complete histological regression was observed
in three of the nine women receiving the highest
dose.132 Plans are underway to initiate a Phase I
trial with a DNA vaccine encoding this modified
E7 linked with CRT (CRT/E7 detox) in patients
with high grade CIN through use of a clinical-
grade gene gun (Huh and Trimble, personal
communication).
Naked RNA replicon vaccines
Naked RNA replicon vaccines provide a new and
interesting approach to HPV vaccination. RNA
replicons can be derived from alphaviruses, such
as the Sindbis virus,133,134 Semliki Forest virus135
and Venezuelan Equine Encephalitis virus.46,136
Self-replication of the RNA replicon allows a sus-
tained level of antigen expression, enhancing im-
munogenicity and making them superior to DNA
vaccines in this manner. The replicon vectors are
modified to exclude viral structural genes, pre-
venting production of viral particles and ensur-
ing safe administration. This also allows repeat
administration without the generation of neu-
tralizing antibodies.
Unfortunately RNA is less stable than DNA.
Attempts to overcome this have used more stable
“suicidal DNA”, which is translated into RNA
replicons within the transfected cell. Transfected
cells eventually undergo apoptosis, alleviating con-
cerns of possible genomic integration and cellu-
lar transformation, an anxiety associated with
DNA vaccines. Despite this advantage, the apop-
tosis leads to poor immunogenicity in DCs di-
rectly transfected with RNA replicons. Apoptosis
can be delayed by suicidal DNA encoding the E7
antigen linked to anti-apoptotic proteins, such as
Bcl-xL, which in mice produces significantly higher
E7-specific CD8 + T cell immune responses than
wild type E7 alone, due to prolonged survival of
DCs.137 Another strategy to overcome the problem
of apoptosis is to exploit the flavivirus Kunjin
(KUN) vector to deliver replicons. The advantage
of KUN is that it does not induce apoptosis in
transfected cells, prolonging antigen presenta-
tion by DCs. DNA-launched KUN replicons en-
coding HPV-16 E7 have been shown to generate
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E7-specific T cell responses and protect mice
against a challenge of E7-expressing tumor.138
RNA replicon-based vaccines can be enhanced
through employment of intercellular spreading
and intracellular targeting strategies as utilised in
DNA based vaccines.134,139,140 Despite the rela-
tive success of RNA replicon vaccines in preclini-
cal models, there has not yet been progression to
clinical trials.
Combinational approach
Prime-boost regimen
The variety of therapeutic vaccines available cre-
ates opportunities to enhance overall potency
through prime-boost regimens. For example, an
initial priming HPV-16 E6/E7 DNA vaccine can
be followed by a boost with recombinant vac-
cinia,141 adenovirus142 or with HPV-16 E6/E7 ex-
pressing tumor cell-based vaccine143 eliciting
greater HPV-specific CD8+ T cell responses than
the vaccines delivered alone. Several prime-boost
studies in mice have shown significantly increased
E7-specific CTL responses, for example through
priming with a Sindbis virus RNA replicon con-
taining HPV-16 E7 linked with hsp70 (E7/hsp70)
and boosting with a recombinant vaccinia virus
encoding E7/hsp70.144
Prime-boost regimens have been evaluated 
in therapeutic clinical trials. TA-CIN (HPV-16 L2/
E6/E7 fusion protein vaccine) has been boosted
with a recombinant vaccinia virus encoding
HPV-16/18 E6/E7 fusion protein (TA-HPV) in
patients with anogenital intraepithelial neopla-
sia. Increases in HPV-16 antigen-specific T cell
mediated immune responses were shown in five
out of 29 patients.145,146 However, this is not a
significant advantage over TA-HPV alone as no
additional efficacy is observed.145 A second study
using TA-HPV followed by TA-CIN in 10 women
with HPV-16+ high grade vulvar intraepithelial
neoplasia reduced lesion size in 3 patients and
created HPV-16 antigen-specific T cell responses
in nine of the 10 vaccinated patients. Unfor-
tunately, there is no correlation between im-
munological and clinical responses.147 A clinical
trial using a DNA vaccine encoding a signalling
peptide (Sig), the mutated E7 antigen [E7(detox)],
and hsp70 [i.e. pNGVL4a/Sig/E7(detox)/Hsp70],
boosted with TA-HPV is currently in progress at
Johns Hopkins University in women with CIN
II/III lesions.148
HPV therapeutic vaccines with other therapies
Combinational approaches employ HPV thera-
peutic vaccines in addition to other therapeutic
modalities such as chemotherapy, radiotherapy
or biotherapeutic agents have been described.
For example, agipenin, a chemotherapeutic agent
that induces apoptotic tumor cell death in vitro
in a dose-dependent manner has been tested in
conjunction with HPV DNA vaccines. Mice bear-
ing E7-expressing tumors treated with apigenin
combined with HPV E7 DNA vaccines show en-
hanced E7-specific CD8+ responses and potent
antitumor effects as apigenin increases tumor
cell susceptibility to the CD8+ cells.149 Low-dose
radiotherapy has also been combined with ther-
apeutic HPV DNA vaccines CRT/E7 (detox) to
control E7-expressing tumors in TC-1 tumor-
bearing mice.150
Tumor microenvironment
Effective immunotherapy for HPV-associated le-
sions must consider modulation of the tumor
microenvironment, which may be hindering the
success of therapeutic vaccines. For example, T reg-
ulatory cells release immunosuppressive cytokines,
such as IL-10151 and transforming growth factor-
β152 in the microenvironment, which can paralyze
T cell function, preventing clearance of HPV-
associated lesions. Depletion of T regulatory cells
from the tumor microenvironment significantly
enhances the potency of therapeutic HPV DNA
vaccines.153 The tumor also induces a state of 
immunosuppression through B7 homolog-1
(B7-H1),154 signal transducer and activator of
transcription-3,155 the enzyme indoleamine 2,3-
dioxygenase,156 galectin-1,157 and MHC class I
polypeptide-related sequence A and B.158 Each of
these are potential targets of immune modula-
tion which may enhance therapeutic effects of
HPV vaccines in the future.159
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Summary
While the approval of Gardasil and Cervarix pre-
ventive HPV vaccines represents a breakthrough
in the development of HPV immunotherapy, the
much-needed therapeutic vaccines require fur-
ther development before full-scale implementa-
tion. The high prevalence of HPV malignancies
and HPV-associated lesions worldwide represents
a pressing need for effective therapeutic HPV vac-
cines. Further study into the tumor microenvi-
ronment and molecular mechanisms impeding
immune attack against HPV will lead to novel
targets for therapeutic intervention in the future.
Discovery of such targets, development of new
adjuvants, and improved understanding of tumor
biology will allow HPV vaccines to be used in
combinational therapies in a synergistic manner
in the future.
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